Your session is about to expire
← Back to Search
S-217622 for COVID-19 (SCORPIO-HR Trial)
SCORPIO-HR Trial Summary
This trial is testing a new drug against placebo to see if it is effective in treating people with COVID-19 who are not expected to benefit from standard care.
SCORPIO-HR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowExclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:SCORPIO-HR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SCORPIO-HR Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a sore throat.I experience headaches.I am experiencing diarrhea.I am not currently using any medications that the study does not allow.I am 18 years old or older.I am currently undergoing chemotherapy or other cancer treatments.I have not taken any experimental drugs for COVID-19 before joining this study.I have tested positive for COVID-19 more than 3 days ago and have not had symptoms for more than 3 days.I have been hospitalized for COVID-19 before, but not for my current infection.I am experiencing symptoms similar to COVID-19.I have been feeling feverish.I experience nausea.I have been experiencing vomiting.I am 65 years old or older.I want to help advance medical research.You have an allergy or sensitivity to any of the ingredients in S-217622 or the placebo used in the study.I have a blocked or stuffy nose.I experience nausea.I experience body or muscle pain.
- Group 1: Placebo
- Group 2: S-217622
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 1 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 5 null
- Follow Ups: You may be asked to continue sharing information regarding the trial for 29 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the harmful effects of S-217622?
"S-217622 has undergone Phase 3 trials, meaning that there is both some efficacy data as well as multiple rounds of safety data. Based on this, our team at Power has given it a safety rating of 3."
Are enrolling any more people in this experiment?
"The trial is open for recruitment, as shown by the information available on clinicaltrials.gov. This includes the initial posting date of 8/3/2022 and the most recent update of 11/1/2022."
In how many cities is this research project being conducted?
"This trial has 22 enrolling patients at locations such as Progressive Clinical Research in Bountiful, SVG Clinical in Las Vegas, and Infusion Associates in Grand Rapids."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- Quantum Clinical Trials: < 24 hours
Average response time
- < 2 Days
Typically responds via
Share this study with friends
Copy Link
Messenger